Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBV mRNA Vaccine in Liver Transplantation for HCC
NCT07077356Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of HBV mRNA vaccine in hepatocellular carcinoma (HCC) (4 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Dose-limiting toxicities at 1 year and Treatment-related adverse events at 1 year. Started Aug 2025; status: recruiting.
02
Drugs
HBV mRNA vaccine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07077356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07077356.